These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38317525)

  • 21. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.
    Doshi JA; Takeshita J; Pinto L; Li P; Yu X; Rao P; Viswanathan HN; Gelfand JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1057-1065.e4. PubMed ID: 26946986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population.
    Lee S; Xie L; Wang Y; Vaidya N; Baser O
    J Manag Care Spec Pharm; 2018 Jul; 24(7):654-663. PubMed ID: 29952710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment patterns of systemic drug use in Japanese patients with plaque psoriasis: A retrospective chart review.
    Tada Y; Komine M; Okubo Y; Habiro K; Tsuritani K; Morita A
    J Dermatol; 2024 Feb; 51(2):210-222. PubMed ID: 38031882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.
    Feldman SR; Zhao Y; Shi L; Tran MH
    J Manag Care Spec Pharm; 2015 Oct; 21(10):874-88. PubMed ID: 26402388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM).
    Sbidian E; Mezzarobba M; Weill A; Coste J; Rudant J
    Br J Dermatol; 2019 Jan; 180(1):86-93. PubMed ID: 29791721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic Burden of Comorbidities in Patients with Psoriasis in the USA.
    Wu JJ; Suryavanshi M; Davidson D; Patel V; Jain A; Seigel L
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):207-219. PubMed ID: 36402940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
    Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    J Comp Eff Res; 2020 Aug; 9(11):767-779. PubMed ID: 32638609
    [No Abstract]   [Full Text] [Related]  

  • 29. Healthcare resource utilization and costs 2 years pre- and post-lumbar spine surgery for stenosis: a national claims cohort study of 22,182 cases.
    Koltsov JCB; Sambare TD; Alamin TF; Wood KB; Cheng I; Hu SS
    Spine J; 2022 Jun; 22(6):965-974. PubMed ID: 35123048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
    Chen KC; Wu CH; Tang CH; Huang KC
    PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence, economic burden, and treatment of acute respiratory tract infection in hematopoietic stem cell transplantation recipients using real world data in Japan: a retrospective claims data analysis.
    Wattanakamolkul K; Nakayama Y
    J Med Econ; 2022; 25(1):870-879. PubMed ID: 35703058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.
    Penso L; Dray-Spira R; Weill A; Pina Vegas L; Zureik M; Sbidian E
    JAMA Dermatol; 2021 Sep; 157(9):1056-1065. PubMed ID: 34287624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis.
    Mahlich J; Alba A; Hadad LE; Leisten MK; Peitsch WK
    Adv Ther; 2019 Jul; 36(7):1684-1699. PubMed ID: 31102203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database.
    Howe A; Eyck LT; Dufour R; Shah N; Harrison DJ
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1236-44. PubMed ID: 25443517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Healthcare resource utilization patterns in psoriasis patients using biologic and conventional treatments in Finland.
    Vesikansa A; Mehtälä J; Aaltonen J; Konttinen R; Tasanen K; Huilaja L
    Front Immunol; 2024; 15():1374829. PubMed ID: 38915400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
    Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
    Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
    Malatestinic W; Nordstrom B; Wu JJ; Goldblum O; Solotkin K; Lin CY; Kistler K; Fraeman K; Johnston J; Hawley LL; Sicignano N; Araujo A
    J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity.
    Murage MJ; Anderson A; Casso D; Oliveria SA; Ojeh CK; Muram TM; Merola JF; Zbrozek A; Araujo AB
    J Dermatolog Treat; 2019 Mar; 30(2):141-149. PubMed ID: 29799292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
    Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
    J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.